SEC 13F Intelligence

Managers / Q4 2023 · view latest →

ABG-WTT Global Life Science Capital Partners GP Ltd

CIK 0001832108 · SUITE 3902, 39/F, EAST TOWER, CHEUNG KONG CNTR II, 10 HARCOURT ROAD, CENTRAL, HONG KONG, K3, 000000 · 852 31219699

Reported Value
$51M
Q4 2023
Positions
4
Filings on Record
22
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Abg-Wtt Global Life Science Capital Partners GP Ltd reported $51M in U.S.-listed holdings across 4 positions for Q4 2023.

The portfolio is heavily concentrated: Rayzebio alone accounts for 94.4% of reported value.

Compared with Q3 2023, the fund opened 1 new position and exited 1.

Portfolio Metrics

Turnover
+6.0%
vs prior filed quarter
Largest Position
+94.4%
Rayzebio
New / Exited
1 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $115MQ4 ’20Q1 ’21: $92MQ2 ’21: $52MQ3 ’21: $15MQ3 ’21Q4 ’21: $7MQ1 ’22: $12MQ2 ’22: $28MQ2 ’22Q3 ’22: $16MQ4 ’22: $6MQ1 ’23: $6MQ1 ’23Q2 ’23: $6MQ3 ’23: $21MQ4 ’23: $51MQ4 ’23Q1 ’24: $42MQ2 ’24: $30MQ3 ’24: $20MQ3 ’24Q4 ’24: $44MQ1 ’25: $38MQ2 ’25: $27MQ2 ’25Q3 ’25: $19MQ4 ’25: $15MQ1 ’26: $12MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Other: 94.4%Common Stock: 5.6%
  • Other · 94.4% · $48M
  • Common Stock · 5.6% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MDVLQMEDAVAIL HOLDINGSNEW+300.6K300.6K+$1M$1M
MEDAVAIL HOLDINGS INCSOLD OUT−300.6K0−$2M$0
RAYZEBIO INCHELD+0778.9K+$31M$48M
RPIDRAPID MICRO BIOSYSTEMS INCHELD+01.04M−$353,021$768,339
LUNGPULMONX CORPHELD+060.2K+$145,694$767,601

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

4 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RAYZEBIO INCCOM94.38%$48M778.9K
2MDVLQMEDAVAIL HOLDINGShistory →COM NEW2.63%$1M300.6K
3RPIDRAPID MICRO BIOSYSTEMS INChistory →CLASS A COM1.50%$768,3391.04M
4LUNGPULMONX CORPhistory →COM1.50%$767,60160.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$12M2May 18, 202613F-HRchanges · EDGAR ↗
Q4 2025$15M2Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$19M2Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$27M2Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$38M4May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$44M4Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$20M3Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$30M3Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$42M3May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$51M4Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$21M4Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$6M3Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$6M3May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$6M3Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$16M3Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$28M3Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$12M3May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$7M2Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$15M2Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$52M2Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$92M2May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$115M2Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.